Avery Heather LaChance, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Dermatology | 12 | 2023 | 907 | 3.410 |
Why?
|
| Scleroderma, Systemic | 7 | 2024 | 346 | 2.810 |
Why?
|
| Dermatomyositis | 7 | 2023 | 261 | 1.850 |
Why?
|
| Lupus Erythematosus, Discoid | 4 | 2023 | 61 | 1.160 |
Why?
|
| Skin Diseases | 5 | 2022 | 1088 | 1.090 |
Why?
|
| Telemedicine | 5 | 2023 | 3105 | 1.080 |
Why?
|
| Scleroderma, Localized | 2 | 2022 | 85 | 0.920 |
Why?
|
| Microstomia | 1 | 2023 | 11 | 0.900 |
Why?
|
| Mixed Connective Tissue Disease | 1 | 2023 | 32 | 0.880 |
Why?
|
| Keloid | 1 | 2023 | 55 | 0.850 |
Why?
|
| Lichen Sclerosus et Atrophicus | 1 | 2023 | 26 | 0.840 |
Why?
|
| Cicatrix, Hypertrophic | 1 | 2023 | 80 | 0.810 |
Why?
|
| Silicone Gels | 1 | 2021 | 39 | 0.740 |
Why?
|
| Connective Tissue Diseases | 2 | 2021 | 284 | 0.730 |
Why?
|
| Skin Abnormalities | 1 | 2021 | 60 | 0.730 |
Why?
|
| Granuloma, Foreign-Body | 1 | 2021 | 41 | 0.730 |
Why?
|
| Buttocks | 1 | 2021 | 110 | 0.720 |
Why?
|
| Medical Tourism | 1 | 2021 | 51 | 0.710 |
Why?
|
| Decontamination | 1 | 2021 | 73 | 0.700 |
Why?
|
| Competency-Based Education | 1 | 2020 | 226 | 0.630 |
Why?
|
| Consumer Health Information | 1 | 2020 | 215 | 0.590 |
Why?
|
| Eosinophilia | 4 | 2023 | 556 | 0.550 |
Why?
|
| Fasciitis | 3 | 2023 | 68 | 0.540 |
Why?
|
| Internship and Residency | 4 | 2022 | 5946 | 0.530 |
Why?
|
| Leg | 1 | 2021 | 1080 | 0.520 |
Why?
|
| Health Policy | 4 | 2021 | 2698 | 0.520 |
Why?
|
| Social Justice | 1 | 2020 | 485 | 0.510 |
Why?
|
| Drug Costs | 3 | 2022 | 1193 | 0.490 |
Why?
|
| Piperidines | 3 | 2021 | 1664 | 0.450 |
Why?
|
| Health Education | 1 | 2020 | 1060 | 0.440 |
Why?
|
| Foot Dermatoses | 1 | 2014 | 46 | 0.440 |
Why?
|
| Physicians | 2 | 2022 | 4588 | 0.440 |
Why?
|
| Drug Approval | 1 | 2021 | 818 | 0.440 |
Why?
|
| Health Services Accessibility | 3 | 2023 | 5508 | 0.430 |
Why?
|
| Skin Diseases, Vesiculobullous | 1 | 2014 | 84 | 0.420 |
Why?
|
| Autoimmune Diseases | 2 | 2022 | 2226 | 0.420 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2021 | 1880 | 0.390 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2020 | 1085 | 0.370 |
Why?
|
| Academic Medical Centers | 2 | 2021 | 2780 | 0.370 |
Why?
|
| Vulnerable Populations | 3 | 2021 | 718 | 0.360 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2014 | 618 | 0.330 |
Why?
|
| Graft vs Host Disease | 1 | 2022 | 3078 | 0.320 |
Why?
|
| Humans | 63 | 2024 | 765968 | 0.320 |
Why?
|
| Lupus Erythematosus, Systemic | 5 | 2023 | 2159 | 0.310 |
Why?
|
| Insurance Coverage | 1 | 2020 | 1944 | 0.310 |
Why?
|
| Mycophenolic Acid | 2 | 2022 | 346 | 0.310 |
Why?
|
| Skin Neoplasms | 5 | 2022 | 5849 | 0.310 |
Why?
|
| Remote Consultation | 2 | 2021 | 240 | 0.300 |
Why?
|
| Referral and Consultation | 1 | 2020 | 3615 | 0.290 |
Why?
|
| Amyloidosis | 1 | 2014 | 885 | 0.260 |
Why?
|
| Skin | 4 | 2022 | 4489 | 0.240 |
Why?
|
| Healthcare Disparities | 1 | 2020 | 3413 | 0.230 |
Why?
|
| Health Expenditures | 3 | 2022 | 2387 | 0.230 |
Why?
|
| Fund Raising | 1 | 2024 | 48 | 0.220 |
Why?
|
| United States | 12 | 2023 | 72903 | 0.220 |
Why?
|
| Hyaluronoglucosaminidase | 1 | 2023 | 138 | 0.210 |
Why?
|
| Cutis Laxa | 1 | 2023 | 29 | 0.210 |
Why?
|
| Injections, Intralesional | 1 | 2023 | 281 | 0.210 |
Why?
|
| Cosmetics | 1 | 2023 | 102 | 0.190 |
Why?
|
| Ointments | 1 | 2021 | 58 | 0.190 |
Why?
|
| Leadership | 2 | 2021 | 1392 | 0.190 |
Why?
|
| Gift Giving | 1 | 2022 | 76 | 0.190 |
Why?
|
| Dominican Republic | 1 | 2021 | 78 | 0.190 |
Why?
|
| Betamethasone | 1 | 2021 | 48 | 0.180 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2024 | 295 | 0.180 |
Why?
|
| Pityriasis Rubra Pilaris | 1 | 2021 | 19 | 0.180 |
Why?
|
| Raynaud Disease | 1 | 2021 | 81 | 0.180 |
Why?
|
| Arthritis, Psoriatic | 1 | 2024 | 216 | 0.180 |
Why?
|
| Melanoma | 2 | 2016 | 5719 | 0.180 |
Why?
|
| Hidradenitis Suppurativa | 1 | 2023 | 176 | 0.170 |
Why?
|
| Erythema | 1 | 2021 | 262 | 0.170 |
Why?
|
| Steroids | 2 | 2022 | 933 | 0.160 |
Why?
|
| Insurance | 1 | 2021 | 115 | 0.160 |
Why?
|
| Education, Medical, Graduate | 2 | 2022 | 2418 | 0.160 |
Why?
|
| Paraproteinemias | 1 | 2021 | 252 | 0.160 |
Why?
|
| Retrospective Studies | 12 | 2023 | 81514 | 0.160 |
Why?
|
| Disinfection | 1 | 2021 | 207 | 0.150 |
Why?
|
| Indians, North American | 1 | 2022 | 354 | 0.150 |
Why?
|
| Masks | 1 | 2021 | 209 | 0.150 |
Why?
|
| Myotonic Dystrophy | 1 | 2019 | 79 | 0.150 |
Why?
|
| Alopecia Areata | 1 | 2021 | 129 | 0.150 |
Why?
|
| Drug Therapy | 1 | 2021 | 504 | 0.150 |
Why?
|
| Botulinum Toxins, Type A | 1 | 2021 | 238 | 0.150 |
Why?
|
| Medicare Part D | 1 | 2022 | 355 | 0.140 |
Why?
|
| Phototherapy | 1 | 2021 | 370 | 0.140 |
Why?
|
| Hydroxychloroquine | 1 | 2021 | 431 | 0.140 |
Why?
|
| Pandemics | 3 | 2021 | 8703 | 0.130 |
Why?
|
| Exanthema | 1 | 2021 | 502 | 0.130 |
Why?
|
| Patients | 1 | 2023 | 910 | 0.130 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2020 | 647 | 0.130 |
Why?
|
| Psoriasis | 1 | 2024 | 919 | 0.130 |
Why?
|
| Acne Vulgaris | 1 | 2021 | 352 | 0.130 |
Why?
|
| Th17 Cells | 1 | 2022 | 786 | 0.120 |
Why?
|
| Sarcoidosis | 1 | 2021 | 532 | 0.120 |
Why?
|
| Video Recording | 1 | 2020 | 969 | 0.120 |
Why?
|
| Medicare | 3 | 2023 | 6823 | 0.120 |
Why?
|
| Pyrimidines | 3 | 2021 | 3047 | 0.120 |
Why?
|
| Cost of Illness | 1 | 2024 | 1950 | 0.110 |
Why?
|
| Curriculum | 2 | 2020 | 3782 | 0.110 |
Why?
|
| Female | 15 | 2024 | 396112 | 0.110 |
Why?
|
| Cross-Sectional Studies | 5 | 2023 | 26318 | 0.110 |
Why?
|
| Communicable Disease Control | 1 | 2020 | 856 | 0.110 |
Why?
|
| Carcinoma, Basal Cell | 1 | 2019 | 566 | 0.110 |
Why?
|
| Lower Extremity | 1 | 2021 | 1226 | 0.110 |
Why?
|
| Administration, Oral | 1 | 2021 | 4015 | 0.100 |
Why?
|
| Income | 1 | 2022 | 1874 | 0.100 |
Why?
|
| Reproducibility of Results | 2 | 2022 | 20124 | 0.100 |
Why?
|
| Toes | 1 | 2014 | 209 | 0.100 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2016 | 728 | 0.100 |
Why?
|
| Macrophage Migration-Inhibitory Factors | 1 | 2011 | 109 | 0.100 |
Why?
|
| Aged | 8 | 2023 | 171117 | 0.090 |
Why?
|
| Tumor Necrosis Factor-alpha | 2 | 2021 | 4348 | 0.090 |
Why?
|
| Rural Population | 1 | 2022 | 2317 | 0.090 |
Why?
|
| Drug Therapy, Combination | 1 | 2021 | 6309 | 0.090 |
Why?
|
| Immunosuppressive Agents | 2 | 2022 | 4209 | 0.090 |
Why?
|
| Adult | 10 | 2023 | 223044 | 0.090 |
Why?
|
| Venous Thromboembolism | 1 | 2023 | 1882 | 0.080 |
Why?
|
| Insurance, Health | 1 | 2022 | 2521 | 0.080 |
Why?
|
| Male | 12 | 2024 | 363698 | 0.080 |
Why?
|
| Biopsy | 1 | 2021 | 6763 | 0.080 |
Why?
|
| Middle Aged | 9 | 2024 | 223009 | 0.080 |
Why?
|
| Massachusetts | 1 | 2021 | 8875 | 0.070 |
Why?
|
| Public Health | 1 | 2021 | 2680 | 0.070 |
Why?
|
| Sex Factors | 1 | 2021 | 10603 | 0.070 |
Why?
|
| Treatment Outcome | 3 | 2023 | 65188 | 0.070 |
Why?
|
| Socioeconomic Factors | 1 | 2020 | 7838 | 0.070 |
Why?
|
| Communication | 1 | 2020 | 3916 | 0.070 |
Why?
|
| Quality of Life | 2 | 2023 | 13462 | 0.060 |
Why?
|
| Combined Modality Therapy | 1 | 2016 | 8529 | 0.060 |
Why?
|
| Anti-Bacterial Agents | 1 | 2021 | 7478 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2021 | 41649 | 0.050 |
Why?
|
| Diagnosis, Differential | 3 | 2021 | 12976 | 0.050 |
Why?
|
| Genetic Testing | 1 | 2014 | 3595 | 0.050 |
Why?
|
| Isotretinoin | 1 | 2022 | 135 | 0.040 |
Why?
|
| Lupus Erythematosus, Cutaneous | 1 | 2021 | 80 | 0.040 |
Why?
|
| Prescriptions | 1 | 2022 | 388 | 0.040 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2023 | 669 | 0.040 |
Why?
|
| Genomics | 1 | 2014 | 5929 | 0.040 |
Why?
|
| Patient Care Management | 1 | 2021 | 303 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2021 | 20659 | 0.040 |
Why?
|
| Personal Satisfaction | 1 | 2022 | 641 | 0.040 |
Why?
|
| Nose | 1 | 2021 | 519 | 0.040 |
Why?
|
| Vasculitis | 1 | 2021 | 527 | 0.030 |
Why?
|
| Temperature | 1 | 2023 | 2226 | 0.030 |
Why?
|
| Costs and Cost Analysis | 1 | 2022 | 1668 | 0.030 |
Why?
|
| Canada | 1 | 2022 | 2119 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2021 | 1187 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2016 | 26346 | 0.030 |
Why?
|
| Prognosis | 1 | 2016 | 29922 | 0.030 |
Why?
|
| Interdisciplinary Communication | 1 | 2021 | 932 | 0.030 |
Why?
|
| False Negative Reactions | 1 | 2016 | 573 | 0.030 |
Why?
|
| Goals | 1 | 2020 | 719 | 0.030 |
Why?
|
| Pyrroles | 1 | 2021 | 1119 | 0.030 |
Why?
|
| Career Choice | 1 | 2020 | 769 | 0.030 |
Why?
|
| Infant | 1 | 2016 | 36386 | 0.030 |
Why?
|
| False Positive Reactions | 1 | 2016 | 955 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2011 | 15880 | 0.030 |
Why?
|
| Extremities | 1 | 2019 | 869 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2016 | 42500 | 0.030 |
Why?
|
| Neoplasms | 1 | 2022 | 22340 | 0.030 |
Why?
|
| Head | 1 | 2019 | 925 | 0.030 |
Why?
|
| Teaching | 1 | 2020 | 1169 | 0.030 |
Why?
|
| Face | 1 | 2019 | 1028 | 0.030 |
Why?
|
| Young Adult | 2 | 2016 | 59889 | 0.030 |
Why?
|
| Breast Neoplasms | 1 | 2020 | 21056 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2011 | 16047 | 0.020 |
Why?
|
| Immunologic Factors | 1 | 2021 | 1587 | 0.020 |
Why?
|
| Qualitative Research | 1 | 2022 | 3139 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 2021 | 4247 | 0.020 |
Why?
|
| Microscopy, Confocal | 1 | 2016 | 1966 | 0.020 |
Why?
|
| Vaccination | 1 | 2022 | 3426 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2011 | 18071 | 0.020 |
Why?
|
| Patient Satisfaction | 1 | 2022 | 3475 | 0.020 |
Why?
|
| Child | 1 | 2016 | 80564 | 0.020 |
Why?
|
| Adolescent | 1 | 2016 | 88835 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2024 | 9249 | 0.020 |
Why?
|
| Comorbidity | 1 | 2021 | 10563 | 0.020 |
Why?
|
| Pain | 1 | 2021 | 5077 | 0.020 |
Why?
|
| Risk Factors | 2 | 2023 | 74840 | 0.020 |
Why?
|
| Immunotherapy | 1 | 2021 | 4752 | 0.020 |
Why?
|
| Age Factors | 1 | 2021 | 18380 | 0.010 |
Why?
|
| Emergency Service, Hospital | 1 | 2023 | 7875 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2023 | 24282 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2016 | 14652 | 0.010 |
Why?
|
| Genotype | 1 | 2011 | 13024 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2023 | 36532 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2011 | 22223 | 0.010 |
Why?
|
| Phenotype | 1 | 2011 | 16721 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2016 | 59489 | 0.010 |
Why?
|